HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target
LARIMAR THERAPEUTICS INC -2.19%
LARIMAR THERAPEUTICS INC LRMR | 8.92 | -2.19% |
HC Wainwright & Co. analyst Edward White reiterates Larimar Therapeutics (NASDAQ:
LRMR) with a Buy and maintains $15 price target.